A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2010

At a glance

  • Drugs Fluticasone propionate; PF 3526299
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 27 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Oct 2009 Planned number of patients changed from 12 to 36 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top